The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Denosumab: A Review in Postmenopausal Osteoporosis
Abstract
Denosumab (Prolia ® ; Pralia ® ) is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The drug is administered via subcutaneous injection once every 6 months and is approved for various indications, including the treatment of postmenopausal (PM) women with osteoporosis at increased/high risk of fracture or failure/intolerance of other osteoporosis therapies (indications featured in this review). Denosumab showed benefit in several phase 3 or 4 studies in PM women with osteoporosis or low bone mineral density (BMD), including the pivotal 3-year double-blind FREEDOM trial and its 7-year open-label extension. Denosumab reduced the risk of vertebral, nonvertebral and hip fractures and increased BMD across skeletal sites versus placebo in FREEDOM, with these benefits maintained over up to 10 years' therapy in the extension. The drug was also more effective in improving BMD than bisphosphonates, including in women switched from a bisphosphonate regimen, in 1-year trials; however, whether these differences translate into differences in anti-fracture efficacy is unclear. Denosumab was generally well tolerated over up to 10 years' treatment, although an increased risk of multiple vertebral fractures was observed after discontinuation of the drug. Thus, denosumab is a key treatment option for PM women with osteoporosis who have an increased/high risk of fracture or failure/intolerance of other osteoporosis therapies, although the potential for multiple verte…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“denosumab, has been shown to have undesirable side effects and, similar to biphosphonates, adversely affects osteoblastogenesis [71]”
From Osteoclasts and Microgravity (2020) · cites this paper as [71]
Citations
Cites
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Black, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,790
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996
Eastell, R., O’Neill, T. W., Hofbauer, L. C., Langdahl, B. L., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 877
Cummings, S. R., Ferrari, S., Eastell, R., Gilchrist, N. L., Jensen, J. B., McClung, M. R., Roux, C., Törring, O., Valter, I., Wang, A. T., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3337 · Cited by 753
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y., Grazette, L. P., Martín, J. S., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 634
Brown, J. P., Prince, R. L., Deal, C. L., Recker, R. R., Kiel, D. P., de Gregorio, L. H., Hadji, P., Hofbauer, L. C., Álvaro‐Gracia, J. M., Wang, H., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0809010 · Cited by 616
Tsourdi, E. A., Langdahl, B. L., Cohen-Solal, M. E., Aubry‐Rozier, B., Eriksen, E. F., Guañabens, N., Obermayer-Pietsch, B. M., Ralston, S. H., Eastell, R., & Zillikens, M. C. (2017) · Bone · doi:10.1016/j.bone.2017.08.003 · Cited by 508
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 491
Research works printed but not linked: 2
- Zhang Y, Zhang L, Li S, et al. Effect of denosumab, a fully human monoclonal antibody to RANKL, on bone mineral density and fractures: a meta-analysis. Int J Clin Exp Med. 2017;10(4):5931–40.
- Insinga RP. Administration costs of denosumab and zoledronic acid for postmenopausal osteoporosis. Am J Pharm Benefits. 2016;8(3):e42–7.
Cited by
Sorted by citations
Current Status of the Diagnosis and Management of Osteoporosis
Aibar-Almazán, A., Voltes-Martínez, A., Castellote-Caballero, Y., Afanador-Restrepo, D. F., Carcelén-Fraile, M. D. C., & López-Ruiz, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169465 · Cited by 412
Osteoporosis pathogenesis and treatment: existing and emerging avenues
Liang, B., Burley, G., Lin, S., & Shi, Y. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00371-3 · Cited by 250
The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis
Seely, K. D., Kotelko, C. A., Douglas, H. E., Bealer, B., & Brooks, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179452 · Cited by 209
RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M., & Fabbri, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1001-2 · Cited by 180
Insights and implications of sexual dimorphism in osteoporosis
Zhang, Y., Xie, N., Sun, X., Nice, E. C., Liou, Y., Huang, C., Zhu, H., & Shen, Z. (2024) · Bone Research · doi:10.1038/s41413-023-00306-4 · Cited by 164
Metadata
- Authors
- Deeks, E. D.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Deeks, Emma D.
- Venue
- Drugs & Aging
- Published
- 2018-02
- Volume
- 35
- Issue
- 2
- Pages
- 163-173
- ISSN
- 1170-229X (ISSN-L)
- 1179-1969
- OpenAlex
- W2792392055
- Cited by
- 169
- References
- 55
- Citations by year
- 2026: 7 · 2025: 23 · 2024: 16 · 2023: 22 · 2022: 32 · 2021: 37 · 2020: 19 · 2019: 10 · 2018: 3
- FWCI
- 18.74
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-03-09)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs & Aging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- denosumab, postmenopausal osteoporosis, RANKL, monoclonal antibodies, fracture risk, vertebral fractures, hip fracture, osteopenia, FREEDOM trial, drug discontinuation, adverse events, long-term treatment
- MeSH terms
- Denosumab, Aged, Clinical Trials as Topic, Female, Humans, Bone Density, Osteoporosis, Postmenopausal, Treatment Outcome, Bone Density Conservation Agents, Fractures, Bone, RANK Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
